Notably, a large randomized trial (named CANTOS) involving more than 10,000 patients with previous MI and high C-reactive protein levels has shown that the IL-1β monoclonal antibody canakinumab could reduce C-reactive protein levels and the incidence rate of recurrent cardiovascular events, without affecting the LDL cholesterol level, but no significant difference in all-cause mortality, probably due to increased risk of fatal infection and sepsis (19). This evidence concerns the gene CRP and Sepsis.